A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
A phase 2 trial of PRL3-zumab in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.
Overview
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors is a phase 2 interventional study registered as NCT04452955 by Intra-IMMUSG Pte Ltd, with 51 participants enrolled, started 2020-12-12 and due to reach its primary completion in 2026-12-01. Interventions recorded: PRL3-zumab.
Similar pages
not linked directly; found by shared links- TrialPhase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Shares Intra-IMMUSG, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPRL3-Zumab in Patients With Advanced Solid Tumors
Shares Intra-IMMUSG, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Shares Parexel, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialBCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Shares Parexel and the tag pipeline.
- TrialA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Shares Parexel and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.